Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from BioCryst ( (BCRX) ) is now available.
In the second quarter of 2025, BioCryst Pharmaceuticals reported a significant financial performance with ORLADEYO net revenue reaching $156.8 million, a 45% increase year-over-year, and an operating profit of $29.8 million, marking a 239% rise. The company also announced plans to retire its remaining term debt through the sale of its European ORLADEYO business, which is expected to further strengthen its financial position. The growth in ORLADEYO’s demand, particularly in the U.S., and the promising pipeline developments, including new drug applications and ongoing trials, highlight BioCryst’s strategic focus on expanding its market presence and delivering value to stakeholders.
The most recent analyst rating on (BCRX) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.
Spark’s Take on BCRX Stock
According to Spark, TipRanks’ AI Analyst, BCRX is a Neutral.
BioCryst’s financial risks, indicated by net losses and negative equity, significantly impact its overall score. While positive earnings call sentiment and corporate events provide some optimism, the stock faces challenges due to bearish technical indicators and unfavorable valuation metrics.
To see Spark’s full report on BCRX stock, click here.
More about BioCryst
BioCryst Pharmaceuticals is a global biotechnology company focused on developing oral small-molecule and protein therapeutics for complement-mediated and other rare diseases. The company has commercialized ORLADEYO, the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of therapies targeting difficult-to-treat diseases.
Average Trading Volume: 4,568,426
Technical Sentiment Signal: Sell
Current Market Cap: $1.66B
For a thorough assessment of BCRX stock, go to TipRanks’ Stock Analysis page.